Published in Curr Neuropharmacol on December 01, 2009
Treatment of neuromyelitis optica: state-of-the-art and emerging therapies. Nat Rev Neurol (2014) 1.53
Immunoglobulin G level variations in treated chronic inflammatory demyelinating polyneuropathy: clues for future treatment regimens? J Neurol (2013) 0.83
The pathogenesis of multifocal motor neuropathy and an update on current management options. Ther Adv Neurol Disord (2015) 0.77
Treatment of neurological autoimmune diseases with immunoglobulins: first insights from the prospective SIGNS registry. J Clin Immunol (2012) 0.76
Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins. J Cent Nerv Syst Dis (2011) 0.75
Predicting the Response to Intravenous Immunoglobulins in an Animal Model of Chronic Neuritis. PLoS One (2016) 0.75
Guillain-Barré syndrome occurring synchronously with systemic lupus erythematosus as initial manifestation treated successfully with low-dose cyclophosphamide. J Community Hosp Intern Med Perspect (2016) 0.75
Rescue effects of intravenous immunoglobulin on optic nerve degeneration in a rat model of neuromyelitis optica. Jpn J Ophthalmol (2016) 0.75
Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science (2006) 8.13
Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol (2008) 6.06
Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science (2001) 4.62
High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet (1981) 4.39
Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol (2008) 3.59
Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med (2001) 3.10
Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol (2008) 3.05
Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease. Lancet (1989) 2.86
Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science (1998) 2.84
Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain (2008) 2.60
Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet (1984) 2.47
Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med (1999) 2.12
The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol (2000) 2.01
Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology (2000) 1.96
Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology (2001) 1.88
Multifocal motor neuropathy. Lancet Neurol (2005) 1.88
Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. Eur J Neurol (2009) 1.73
Plasma and gamma-globulin infusion in chronic inflammatory polyneuropathy. J Neurol Sci (1985) 1.67
Treatment of Guillain-Barré syndrome with high-dose gammaglobulin. Neurology (1988) 1.66
Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity. Proc Natl Acad Sci U S A (2007) 1.66
IVIg therapy in brain inflammation: etiology-dependent differential effects on leucocyte recruitment. Brain (2004) 1.61
Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. J Immunol (1989) 1.46
Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry (1995) 1.31
F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med (2003) 1.28
Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis. Clin Exp Immunol (1991) 1.20
Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contain antiidiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies. J Clin Invest (1990) 1.20
Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev (2002) 1.20
Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology (1994) 1.18
High-dose intravenous gammaglobulin for myasthenia gravis. Lancet (1984) 1.14
Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta chain. Proc Natl Acad Sci U S A (1992) 1.13
The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther (2004) 1.13
Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood (1994) 1.12
Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst (2006) 1.11
Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain (2001) 1.09
Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology (2002) 1.06
Anti-idiotypes against autoantibodies and alloantibodies to VIII:C (anti-haemophilic factor) are present in therapeutic polyspecific normal immunoglobulins. Clin Exp Immunol (1988) 1.03
Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg). Clin Exp Immunol (1993) 1.01
Anti-CD4 activity of normal human immunoglobulin G for therapeutic use. (Intravenous immunoglobulin, IVIg). Ther Immunol (1994) 0.99
Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve (2008) 0.97
The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues. Clin Immunol Immunopathol (1992) 0.97
High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes. Blood (1996) 0.95
Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg). Blood (1999) 0.95
A role for IL-1 receptor antagonist or other cytokines in the acute therapeutic effects of IVIg? Blood (2006) 0.95
Dose of intravenous immunoglobulins in chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst (2006) 0.95
In vitro inhibition of tumour necrosis factor-alpha and interleukin-6 production by intravenous immunoglobulins. Br J Haematol (1995) 0.95
Antibodies to C-C chemokine receptor 5 in normal human IgG block infection of macrophages and lymphocytes with primary R5-tropic strains of HIV-1. J Immunol (2001) 0.91
A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol (1996) 0.90
Inhibition of complement-mediated red cell lysis by immunoglobulins is dependent on the IG isotype and its C1 binding properties. Scand J Immunol (1995) 0.89
Human immunoglobulin preparations for intravenous use prevent experimental autoimmune uveoretinitis. Int Immunol (1993) 0.88
IVIg in idiopathic autoimmune neuropathies: analysis in the light of the latest results. J Neurol (2005) 0.88
Modulation of endothelial cell function by normal polyspecific human intravenous immunoglobulins: a possible mechanism of action in vascular diseases. Am J Pathol (1998) 0.88
The role of complement and complement regulators in mediating motor nerve terminal injury in murine models of Guillain-Barré syndrome. J Neuroimmunol (2008) 0.88
Pooled human gammaglobulin modulates surface molecule expression and induces apoptosis in human B cells. Am J Transplant (2003) 0.87
Observations on the mode of action of normal immunoglobulin at high doses. Immunol Rev (1994) 0.87
Soluble HLA class I and class II concentrations in commercial immunoglobulin preparations. Tissue Antigens (1992) 0.86
I.v. immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barré syndrome. Neurology (1999) 0.86
Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev (2001) 0.86
Normal human immunoglobulin suppresses experimental myasthenia gravis in SCID mice. Eur J Immunol (1999) 0.85
C5 inhibitor rEV576 protects against neural injury in an in vitro mouse model of Miller Fisher syndrome. J Peripher Nerv Syst (2008) 0.85
First results of immunotherapy with immunoglobulin G in multiple sclerosis patients. Eur Neurol (1983) 0.85
Intravenous immune globulins in patients with Guillain-Barré syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatry (2001) 0.84
The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model. Int Immunol (2007) 0.84
Intravenous immunoglobulins suppress immunoglobulin productions by suppressing Ca(2+)-dependent signal transduction through Fc gamma receptors in B lymphocytes. Scand J Immunol (1994) 0.82
Immunoglobulins for intravenous use inhibit TNF alpha cytotoxicity in vitro. Immunol Invest (1998) 0.80
Intravenous gamma-globulin inhibits binding of anti-GM1 to its target antigen. Ann Neurol (1996) 0.79
Promotion of remyelination by polyclonal immunoglobulin in Theiler's virus-induced demyelination and in multiple sclerosis. J Neurol Neurosurg Psychiatry (1994) 0.79
In-vitro inhibition of antiplatelet autoantibodies by intravenous immunoglobulins and Rh immunoglobulins. J Postgrad Med (1998) 0.78
Intravenous immunoglobulin modulates lymphocyte CD54 and monocyte FcgammaRII expression in patients with chronic inflammatory neuropathies. J Neuroimmunol (2003) 0.77
In vitro inhibition by intravenous immunoglobulin of human T cell-dependent B cell differentiation induced by staphylococcal superantigens. Clin Immunol Immunopathol (1996) 0.77
High-dose intravenous gammaglobulin for myasthenia gravis. Lancet (1984) 0.76
Theoretical mechanisms by which immunoglobulin therapy might benefit myasthenia gravis. Clin Immunol Immunopathol (1989) 0.76
Intravenous immune globulin therapy of lupus nephritis: use of pathogenic anti-DNA-reactive IgG. Clin Exp Immunol (1996) 0.76
Increased in vitro uptake of the complement C3b in the serum of patients with Guillain-Barré syndrome, myasthenia gravis and dermatomyositis. J Neuroimmunol (1996) 0.76
Identification of novel and recurrent CACNA1A gene mutations in fifteen patients with episodic ataxia type 2. J Neurol Sci (2010) 0.96
Chronic inflammatory demyelinating polyradiculoneuropathy. Presse Med (2013) 0.87
Overview of the pathogenesis and treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulins. Biologics (2010) 0.86
Common and less common peripheral nerve disorders associated with diabetes. Curr Diabetes Rev (2012) 0.84
Insulin neuritis and diabetic cachectic neuropathy: a review. Curr Diabetes Rev (2013) 0.82
Subcutaneous immunoglobulin therapy for inflammatory neuropathy: current evidence base and future prospects. J Neurol Neurosurg Psychiatry (2013) 0.82
Charcot-Marie-Tooth disease due to the Thr124Met mutation in the myelin protein zero gene associated with multiple sclerosis. J Peripher Nerv Syst (2005) 0.82
Optic neuropathy associated with CANOMAD: description of 2 cases. Muscle Nerve (2011) 0.80
Knowledge of TIA among general practitioners and emergency department physicians. A questionnaire survey in a French semi-rural area. Clin Neurol Neurosurg (2013) 0.80
Facial onset sensory motor neuronopathy: an immunoglobulin-responsive case. J Clin Neuromuscul Dis (2013) 0.80
Rapidly progressive bilateral ophthalmoplegia and enlarging sellar mass caused by amelanotic melanoma. J Neuroophthalmol (2006) 0.79
Demyelinating neuropathy with anti-CRMP5 antibodies predating diagnosis of breast carcinoma: favorable outcome after cancer therapy. Muscle Nerve (2011) 0.77
Diagnosis, epidemiology and treatment of inflammatory neuropathies. Br J Hosp Med (Lond) (2012) 0.77
Steroid-induced inflammatory neuropathy in a patient on tumor necrosis factor-α antagonist therapy. J Clin Neuromuscul Dis (2010) 0.76
Intracranial hypertension induced by rofecoxib. Headache (2005) 0.76
Multi-focal motor neuropathy: one treatment works but many uncertainties remain. Expert Opin Biol Ther (2011) 0.75
Immunomodulation in inflammatory neuropathies: rationale and safety. Curr Drug Saf (2013) 0.75
Chronic inflammatory demyelinating polyneuropathy associated with alopecia totalis and Sjögren syndrome. Muscle Nerve (2012) 0.75
A rare cause of late-onset cerebellar ataxia: Erdheim-Chester disease. Cerebellum (2013) 0.75
Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev (2017) 0.75
Neuropathy associated with lansoprazole treatment. Muscle Nerve (2005) 0.75
Charcot-Marie-Tooth disease due to novel myelin protein zero mutation presenting as late-onset remitting sensory neuropathy. J Clin Neuromuscul Dis (2010) 0.75
Immunoglobulin-responsive dysautonomia in Sjögren's syndrome. J Neurol (2007) 0.75
Intracranial hypertension associated with transverse myelitis. J Neuroophthalmol (2004) 0.75
Vertical optokinetic nystagmus in Parkinson's disease. Mov Disord (2009) 0.75
Juvenile myoclonic epilepsy in an elderly patient. Age Ageing (2006) 0.75